Drug intelligence / Profile preview

ANN-101

Development stage: Preclinical
Lead developer: Anodyne Nanotech
Modality: Peptides
Administration: Transdermal

Overview

ANN-101 is a once-weekly transdermal GLP-1 receptor agonist patch being developed by Anodyne Devices for the treatment of obesity. It utilizes the proprietary HeroPatch™ microneedle platform, which consists of dissolvable microneedles designed to deliver biologics and peptides through the skin in a needle-free, controlled manner. By providing sustained delivery over a one-week period, ANN-101 aims to offer a more patient-friendly alternative to traditional subcutaneous injections of GLP-1 medications. The asset is currently in the IND-enabling phase with clinical trials anticipated to begin in 2026.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on ANN-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANN-101.

Explore the full profile